Status:

UNKNOWN

Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress

Lead Sponsor:

The Catholic University of Korea

Collaborating Sponsors:

MSD Korea Ltd.

Conditions:

Type 2 Diabetes

Eligibility:

All Genders

18-80 years

Phase:

PHASE4

Brief Summary

This research will focus on the effect of Sitagliptin on 24 hour glycemic excursion and improvement of oxidative stress markers compared to long acting sulphonylurea Glimepiride in type 2 diabetic pat...

Detailed Description

Sitagliptin might improve not only the mean glycemic control during study period but also 24 hour glycemic fluctuation by restoring the physiologic pattern of insulin secretion. Furthermore decrease p...

Eligibility Criteria

Inclusion

  • patients with type 2 diabetes
  • duration of diabetes less than 10 years
  • HbA1c 6.5-8.0%
  • BMI 20-30
  • on stable dose of metformin (more than 1000mg) for at least 2 months

Exclusion

  • having oral hypoglycemic agents other than metformin
  • using insulin
  • serum creatinin \>= 1.5 mg/dL
  • SGOT, SGPT \>= 90
  • ischemic heart disease
  • congestive heart failure (NYHA class \>=2)
  • severe diabetic complication (PDR, CRF, CVA)
  • on medication affecting glucose profile (such as steroid)
  • infectious disease
  • malignancy
  • pregnant or breast-feeding woman

Key Trial Info

Start Date :

June 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2010

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT00699322

Start Date

June 1 2008

End Date

June 1 2010

Last Update

October 29 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Kangnam St. Mary's hospital

Seoul, South Korea, 137-701